The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...

This program offers prescription weight loss drugs, coaching and ongoing ... A person typically takes one dose per week. Zepbound single-dose vials are available in 2.5 mg and 5 mg doses, while ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Zepbound is an ... breathing interruptions per hour. Furthermore, up to 50% of participants no longer exhibited symptoms of OSA. The medication also promotes weight loss, with patients losing ...

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...